Optimizing mobilization strategies in difficult-to-mobilize patients: The role of plerixafor-Reference-Cited by-同舟云学术

Optimizing mobilization strategies in difficult-to-mobilize patients: The role of plerixafor

Published:2015-08 Issue:1 Volume:53 Page:23-29
ISSN:1473-0502
Container-title:Transfusion and Apheresis Science
language:en
Short-container-title:Transfusion and Apheresis Science

Author:

Goker Hakan,Etgul Sezgin,Buyukasik Yahya

Publisher

Elsevier BV

Subject

Hematology

Reference114 articles.

1. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome;Attal;N Engl J Med,1996

2. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial;Schmitz;Lancet,2002

3. Graft-versus-leukemia reactions after bone marrow transplantation;Horowitz;Blood,1990

4. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma;Child;N Engl J Med,2003

5. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation;Weiden;Transplant Proc,1981

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of upfront plerixafor use for mobilization in germ cell tumor patients;Hematology, Transfusion and Cell Therapy;2024-03

2. Plerixafor use in autologous hematopoietic stem cell mobilization: Experience from a single center in Southern India;Asian Journal of Transfusion Science;2022

3. Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update;Journal of Blood Medicine;2021-06

4. Medical database analysis of japanese multiple myeloma patients with planned stem cell transplantation (MEDALIST) – a focus on healthcare resource utilization and cost;International Journal of Hematology;2020-10-15

5. CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent;Pharmacological Research;2020-09